These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37737962)

  • 1. Analysis of Pregnancy Outcomes Following Exposure to Intramuscular Interferon Beta-1a: The AVONEX
    Weinstock-Guttman B; Ross AP; Planton J; White K; Pandhi A; Greco A; Kumar A; Everage N; Vignos M
    Drugs Real World Outcomes; 2023 Dec; 10(4):503-511. PubMed ID: 37737962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
    Kaplan S; Dragut CF; Ghimpeteanu A
    Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.
    Klehmet J; Begus-Nahrmann Y; Taipale K; Niemczyk G; Rehberg-Weber K
    Ther Adv Neurol Disord; 2023; 16():17562864231214041. PubMed ID: 38107443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
    Sandberg-Wollheim M; Frank D; Goodwin TM; Giesser B; Lopez-Bresnahan M; Stam-Moraga M; Chang P; Francis GS
    Neurology; 2005 Sep; 65(6):802-6. PubMed ID: 16093457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
    Coyle PK; Sinclair SM; Scheuerle AE; Thorp JM; Albano JD; Rametta MJ
    BMJ Open; 2014 May; 4(5):e004536. PubMed ID: 24821713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of interferon beta exposure on birth outcome and child development - Results from the post-authorisation safety study PRIMA.
    Klehmet J; Begus-Nahrmann Y; Taipale K; Niemczyk G; Rehberg-Weber K
    Mult Scler Relat Disord; 2023 Sep; 77():104844. PubMed ID: 37393802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
    Lampl C; You X; Limmroth V
    Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
    Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
    Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
    Ephross SA; Sinclair SM
    Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
    Vannappagari V; Thorne C;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):371-378. PubMed ID: 30939532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry.
    Hellwig K; Rog D; McGuigan C; Houtchens MK; Bruen DR; Mokliatchouk O; Branco F; Peng X; Everage NJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34815321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.